QGEN vs ILMN vs NEOG vs EXAS vs NTRA

For growth investors, Natera, Inc.

(NTRA) is the stronger pick with 35. 9% revenue growth year-over-year, versus -3. 2% for Neogen Corporation (NEOG). Qiagen N. V. (QGEN) offers the better valuation at 16. 4x trailing P/E (13. 4x forward), making it the more compelling value choice. Analysts rate Illumina, Inc. (ILMN) a "Buy" — based on 50 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Qiagen N.

V. (QGEN) is the cheapest at 16. 4x versus Illumina, Inc. at 25. 5x. On forward P/E, Qiagen N. V. is actually cheaper at 13. 4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Qiagen N. V. wins at 0. 30x versus Illumina, Inc. 's 6. 33x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Natera, Inc.

(NTRA) delivered a total return of +115. 9%, compared to -80. 6% for Neogen Corporation (NEOG). Over 10 years, the gap is even starker: NTRA returned +20. 9% versus NEOG's -49. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Exact Sciences Corporation (EXAS) is the lower-risk stock at 0.

12β versus Neogen Corporation's 1. 83β — meaning NEOG is approximately 1418% more volatile than EXAS relative to the S&P 500. On balance sheet safety, Natera, Inc. (NTRA) carries a lower debt/equity ratio of 13% versus 105% for Exact Sciences Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Natera, Inc.

(NTRA) is pulling ahead at 35. 9% versus -3. 2% for Neogen Corporation (NEOG). On earnings-per-share growth, the picture is similar: Qiagen N. V. grew EPS 436. 8% year-over-year, compared to -114. 6% for Neogen Corporation. Over a 3-year CAGR, NTRA leads at 41. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Qiagen N.

V. (QGEN) is the more profitable company, earning 20. 3% net margin versus -122. 1% for Neogen Corporation — meaning it keeps 20. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: QGEN leads at 24. 9% versus -13. 4% for NTRA. At the gross margin level — before operating expenses — EXAS leads at 69. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Qiagen N. V. (QGEN) is the more undervalued stock at a PEG of 0. 30x versus Illumina, Inc. 's 6. 33x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Qiagen N. V. (QGEN) trades at 13. 4x forward P/E versus 582. 8x for Exact Sciences Corporation — 569. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for QGEN: 41. 7% to $47. 50.

In this comparison, QGEN (0.

8% yield) pays a dividend. ILMN, NEOG, EXAS, NTRA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Exact Sciences Corporation (EXAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

12), +1669% 10Y return). Neogen Corporation (NEOG) carries a higher beta of 1. 83 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EXAS: +1669%, NEOG: -49. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: QGEN is a small-cap deep-value stock; ILMN is a mid-cap quality compounder stock; NEOG is a small-cap quality compounder stock; EXAS is a mid-cap high-growth stock; NTRA is a mid-cap high-growth stock. QGEN pays a dividend while ILMN, NEOG, EXAS, NTRA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.